(Source: Sosei Group Corporation) b01ce187-e6bd-4b0f-87f4-3319115b1bea.pdf Initiation of Phase 1 Clinical Study with Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment from AstraZeneca to Heptares Tokyo, Japan July 6 2016: Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) today announces Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation, reported that it has been notified today by its partner AstraZeneca that the first subject has been dosed with immuno-oncology candidate HTL1071 (AZD4635) in a Phase 1 clinical study, triggering a US$10 million payment from AstraZeneca. The first-in-human study is...
↧